Mfg. of: Bulk Drugs, Drug Intermediates & Speciality Chemicals



Date: 3rd July, 2020

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001
Scrip Code: 540359

Dear Sir / Madam,

Sub: Continuation of closure of Trading Window

In continuation to our letter dated 30th March, 2020 intimating closure of Trading Window of the Company w.e.f. 1st April, 2020 till 48 hours after the declaration of Audited Financial Results for the financial year ended on 31st March, 2020.

In this regard, we hereby inform that the Audited Financial Results for the financial year ended on 31st March, 2020 are yet to be submitted in view of extension given by SEBI vide its circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/106 dated 24th June, 2020 and hence, in compliance with BSE's Circular No. LIST/COMP/O1/2019-20 dated 2"" April, 2019 and Company's Code of Practices and Procedures and Code of Conduct to Regulate, Monitor and Report Trading in Securities and SEBI (Prohibition of Insider Trading) Regulations, 2015 the 'Trading Window' of the Company shall continue to remain closed till 48 hours after the declaration of Unaudited Financial Results for the quarter ended on 30th June, 2020.

This is for your information and record.

Thanking you,

Yours faithfully,

For Parmax Pharma Limited

Yash J. Vora

Company Secretary and Compliance Officer